Diagnostics R&D expanded: the Promarker™ Pipeline

The Company is pleased to provide the following market update on its expanding diagnostics development pipeline.

Of note is the COVID-19 research programs initiated to develop a rapid diagnostic test for the identification of the SARS-CoV-2 virus, and to isolate biomarkers that give insights into the progression of the COVID-19 disease.

Media Release


  • This field is for validation purposes and should be left unchanged.